接种COVID-19疫苗后突发性听力损失
研究未发现任何COVID-19疫苗接种后SSNHL风险增加;BNT162b2疫苗3剂调整发病率比分别为0.8、0.9和1.0。SARS-CoV-2感染与SSNHL发病率增加无关联。
要点
- 研究未发现任何COVID-19疫苗接种后SSNHL风险增加。
- BNT162b2疫苗3剂调整发病率比分别为0.8、0.9和1.0。
- SARS-CoV-2感染与SSNHL发病率增加无关联。
核心结论
- 本队列研究结果未显示COVID-19疫苗接种后SSNHL风险增加的证据。
- 研究校正了既往疾病和其他潜在混杂因素。
- 结果基于专科诊疗中的诊断编码,仍需在能够评估听力损失程度的机构中验证。
研究设计与样本
- 研究期间为2019年1月1日至2022年4月20日。
- 纳入研究期间存活或出生者,排除2015至2018年根据专科诊疗诊断编码(ICD-10代码H91.2)作为主要或次要诊断的SSNHL患者。
- 暴露:主要风险期为每次COVID-19疫苗接种后0至54天;次要风险期为每次接种后55天至后续接种;次要分析包括SARS-CoV-2 PCR阳性后0至54天风险时间。
主要发现
- 芬兰COVID-19疫情前,每年18.7/10万人被诊断为SSNHL。
- 研究数据提示任何COVID-19疫苗接种后SSNHL风险均未增加。
- BNT162b2疫苗3剂调整发病率比(95%CI)分别为0.8(95%CI,0.6-1.0)、0.9(95%CI,0.6-1.2)和1.0(95%CI,0.7-1.4)。
- SARS-CoV-2感染与SSNHL发病率增加之间无关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 结果基于专科诊疗中的诊断编码,仍需在能够评估听力损失程度的机构中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Spontaneous adverse reaction reports of sudden hearing loss have been observed, and a population-based cohort study conducted in Israel showed an increase in the incidence of sudden sensorineural hearing loss (SSNHL) following vaccination with messenger RNA COVID-19 vaccine BNT162b2 (Pfizer-BioNTech). However, in this setting, the possibility of confounding remained. OBJECTIVE: To assess a potential association between COVID-19 vaccinations and SSNHL. DESIGN, SETTING, AND PARTICIPANTS: This register-based country-wide retrospective cohort study of 5.5 million Finnish residents was conducted from January 1, 2019, to April 20, 2022, and included all individuals who were identified from the population information system who were alive or born during the study period except individuals who had SSNHL during 2015 to 2018 according to specialized care derived diagnosis codes for SSNHL (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision [ICD-10] code H91.2) as a primary or secondary diagnosis. EXPOSURES: The a priori primary risk period was 0 to 54 days following each COVID-19 vaccination. The risk periods for different vaccine doses did not overlap so that a later vaccine exposure ended the previous risk period. The secondary risk period was from 55 days following each COVID-19 vaccination until a subsequent COVID-19 vaccination. A secondary analysis included a risk time from 0 to 54 days following a positive polymerase chain reaction test result for SARS-CoV-2. MAIN OUTCOMES AND MEASURES: The incidences of SSNHL following COVID-19 vaccination were compared with the incidences before the COVID-19 epidemic in Finland. The Poisson regression model included calendar time, age, sex, diabetes, cardiovascular disease, other chronic diseases, and the number of visits in primary health care. RESULTS: For the 5.5 million Finnish residents included in the study, the comparison time comprised 6.5 million person-years, the primary risk time of 1.7 million person-years, and the secondary risk time of 2.1 million person-years. Before the COVID-19 epidemic in Finland, 18.7/100 000 people received a diagnosis of SSNHL annually. The study data suggested no increased risk for SSNHL following any COVID-19 vaccination. In particular, adjusted incidence rate ratios with 95% confidence intervals for the BNT162b2 vaccine's 3 doses were 0.8 (95% CI, 0.6-1.0), 0.9 (95% CI, 0.6-1.2), and 1.0 (95% CI, 0.7-1.4), respectively. There was no association between SARS-CoV-2 infection and an increased incidence of SSNHL. CONCLUSIONS AND RELEVANCE: The results of this cohort study show no evidence of an increased risk of SSNHL following COVID-19 vaccination. The study accounted for previous disease and other potential confounding factors. These results are based on diagnosis codes in specialized care but still need to be verified in settings that are capable of evaluating the degree of hearing loss.
引用
- Nieminen TA, Kivekäs I, Artama M, et al. Sudden Hearing Loss Following Vaccination Against COVID-19. JAMA Otolaryngol Head Neck Surg. 2023. PMID: 36520464. doi:10.1001/jamaoto.2022.4154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。